# Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

> **NCT05065736** · EARLY_PHASE1 · RECRUITING · sponsor: **Roberto Vargas** · enrollment: 4 (estimated)

## Conditions studied

- Metastatic Cancer
- Carcinoma
- Adenocarcinoma

## Interventions

- **DRUG:** 18F-Clofarabine

## Key facts

- **NCT ID:** NCT05065736
- **Lead sponsor:** Roberto Vargas
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065736, "Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05065736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*